Wilson Martin sold $128K of RCKT
Wilson Martin (General Counsel) sold 53,389 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $2.39 ($0.13M total) on 2026-11-05.
How this was made
The 30-second read
Why it matters
The disclosure provides a fresh, company-specific datapoint on insider selling by the General Counsel, which can marginally influence sentiment but is unlikely to drive fundamentals by itself.
Market read
Traders may monitor insider activity as a sentiment input, but the transaction size is modest and lacks a stated fundamental trigger.
What to watch
The filing notes no pre-arranged 10b5-1 plan, but the article does not provide the reason for sale, tax considerations, or whether other insiders are selling/buying concurrently.
Background
The article is an SEC Form 4 insider transaction disclosure for Rocket Pharmaceuticals.
Ticker impact
Rocket Pharmaceuticals Form 4 shows insider Wilson Martin sold 53,389 shares in an open-market transaction for about $127.8K.
Shares may face slight near-term sentiment pressure, though impact is likely limited given the modest transaction value.
This is a primary SEC Form 4 insider sale disclosure. The article provides exact share count, price, and post-transaction holdings, but the dollar amount is relatively small and there is no stated company-specific catalyst.
Market effects
Minimal, as this is a single-company insider sale with no sector-wide regulatory or clinical catalyst.
None indicated.
None indicated.
Counterpoint
Insider sales can be routine liquidity events and do not necessarily reflect negative fundamentals, especially without evidence of broader selling patterns.
Key entities
- issuerRocket Pharmaceuticals, Inc.
US-listed company whose insider transaction is disclosed on Form 4.
- insiderWilson Martin
General Counsel who sold 53,389 shares in an open-market sale.